CN115175902A - 一类用作激酶抑制剂的化合物及其应用 - Google Patents

一类用作激酶抑制剂的化合物及其应用 Download PDF

Info

Publication number
CN115175902A
CN115175902A CN202180013936.6A CN202180013936A CN115175902A CN 115175902 A CN115175902 A CN 115175902A CN 202180013936 A CN202180013936 A CN 202180013936A CN 115175902 A CN115175902 A CN 115175902A
Authority
CN
China
Prior art keywords
group
compound
alkyl
cycloalkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180013936.6A
Other languages
English (en)
Other versions
CN115175902B (zh
Inventor
李钧
牛成山
梁阿朋
郭中伟
吴豫生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deuracor Therapeutic Inc
Zhengzhou Tongyuankang Pharmaceutical Co ltd
Original Assignee
Deuracor Therapeutic Inc
Zhengzhou Tongyuankang Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deuracor Therapeutic Inc, Zhengzhou Tongyuankang Pharmaceutical Co ltd filed Critical Deuracor Therapeutic Inc
Publication of CN115175902A publication Critical patent/CN115175902A/zh
Application granted granted Critical
Publication of CN115175902B publication Critical patent/CN115175902B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

式Ⅰ所示的激酶抑制剂的化合物或其药学上可以接受的盐、溶剂化物或前药。该化合物对EGFR和Her2外显子20插入突变、EGFR外显子19缺失和外显子21的L858R点突变具有良好的抑制活性。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202180013936.6A 2020-03-13 2021-03-15 一类用作激酶抑制剂的化合物及其应用 Active CN115175902B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010175791 2020-03-13
CN2020101757917 2020-03-13
PCT/CN2021/080892 WO2021180238A1 (zh) 2020-03-13 2021-03-15 一类用作激酶抑制剂的化合物及其应用

Publications (2)

Publication Number Publication Date
CN115175902A true CN115175902A (zh) 2022-10-11
CN115175902B CN115175902B (zh) 2024-07-26

Family

ID=77672025

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180013936.6A Active CN115175902B (zh) 2020-03-13 2021-03-15 一类用作激酶抑制剂的化合物及其应用

Country Status (4)

Country Link
US (1) US20230150975A1 (zh)
EP (1) EP4119553A4 (zh)
CN (1) CN115175902B (zh)
WO (1) WO2021180238A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116283914A (zh) * 2021-12-01 2023-06-23 上海艾力斯医药科技股份有限公司 一类嘧啶类化合物、其制备方法及应用
KR20240110861A (ko) 2022-04-01 2024-07-16 티와이케이 메디슨즈, 인코포레이티드 키나아제 억제제로 사용되는 화합물 및 이의 용도
CN115925618A (zh) * 2023-01-06 2023-04-07 河南省科学院化学研究所有限公司 一种2-(2,2,2-三氟乙氧基)-6-氯-3-氨基吡啶的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761544A (zh) * 2014-01-03 2015-07-08 南京波尔泰药业科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN105085489A (zh) * 2014-11-05 2015-11-25 上海页岩科技有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106559991A (zh) * 2014-06-19 2017-04-05 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN112292378A (zh) * 2019-05-22 2021-01-29 上海翰森生物医药科技有限公司 含吲哚类衍生物抑制剂、其制备方法和应用
CN114174269A (zh) * 2019-07-26 2022-03-11 南京明德新药研发有限公司 作用于egfr和erbb2的嘧啶类化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3205650B1 (en) * 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
CN108069939B (zh) * 2016-11-16 2020-03-10 中国科学院上海药物研究所 含有共轭联烯酰胺结构的化合物、其制备方法、药物组合物和用途
CN108191861B (zh) * 2018-03-01 2020-10-02 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺
CN110790749B (zh) * 2018-08-03 2023-07-14 北京普祺医药科技股份有限公司 一种含氮杂环化合物、药物组合物以及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761544A (zh) * 2014-01-03 2015-07-08 南京波尔泰药业科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN106559991A (zh) * 2014-06-19 2017-04-05 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
CN105085489A (zh) * 2014-11-05 2015-11-25 上海页岩科技有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN112292378A (zh) * 2019-05-22 2021-01-29 上海翰森生物医药科技有限公司 含吲哚类衍生物抑制剂、其制备方法和应用
CN114174269A (zh) * 2019-07-26 2022-03-11 南京明德新药研发有限公司 作用于egfr和erbb2的嘧啶类化合物

Also Published As

Publication number Publication date
EP4119553A4 (en) 2023-12-20
US20230150975A1 (en) 2023-05-18
WO2021180238A1 (zh) 2021-09-16
EP4119553A1 (en) 2023-01-18
CN115175902B (zh) 2024-07-26

Similar Documents

Publication Publication Date Title
CN107840846B (zh) 一种含嘧啶环的化合物、egfr抑制剂及其应用
WO2021073439A1 (zh) 用于抑制shp2活性的吡嗪衍生物
CN107382879B (zh) 一种嘧啶类化合物、egfr抑制剂及其应用
CN105837576B (zh) Btk抑制剂
CN115175902A (zh) 一类用作激酶抑制剂的化合物及其应用
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
TWI694078B (zh) 吡咯並三嗪類衍生物、其製備方法及其用途
CN110092787B (zh) 一种化合物或其药用盐或组合物的制备及应用
TW201704237A (zh) 適用於治療與ｋｉｔ及ｐｄｆｇｒ相關之病症的組合物
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
WO2016011979A1 (zh) 2，4-二取代7H-吡咯并[2，3-d]嘧啶衍生物、其制法与医药上的用途
WO2017016463A1 (zh) Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
CN111961034A (zh) 用作ret激酶抑制剂的化合物及其应用
AU2019218187A1 (en) Dioxinoquinoline compounds, preparation method and uses thereof
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
CN114907341A (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
WO2021164793A1 (zh) 用作激酶抑制剂的化合物及其应用
CN109666022B (zh) 三氮唑衍生物及其制备方法和用途
CN115536660A (zh) 苄氨基取代的杂多环化合物及其组合物、制剂和用途
CN114026090B (zh) 一类抑制egfr激酶的化合物及其制备方法和用途
US20050075354A1 (en) Complexes of E-2-Methoxy-N(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinzazolin-6-YL}-allyl)-acetamide, their method of production, and use
CN110294742A (zh) 并环类ask1抑制剂及其应用
TWI855259B (zh) 用作激酶抑制劑的化合物及其用途
CN111606888B (zh) 吡咯类衍生物及其制备方法与应用
CN114075141A (zh) 阿片受体“偏向性”配体、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant